CC
HRTX icon

Clearline Capital’s Heron Therapeutics HRTX Stock Holding History

Clearline Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.86M Sell
11,383,961
-851,278
-7% -$683K 0.29% 66
2026
Q1 		$9.79M Hold
12,235,239
– – 0.51% 43
2025
Q4 		$15.9M Buy
12,235,239
+2,522,712
+26% +$3.11M 0.78% 27
2025
Q3 		$12.2M Buy
9,712,527
+8,855,361
+1,033% +$14M 0.56% 42
2025
Q2 		$1.77M Sell
857,166
-202,745
-19% -$414K 0.07% 85
2025
Q1 		$2.33M Sell
1,059,911
-750,572
-41% -$1.46M 0.14% 80
2024
Q4 		$2.77M Sell
1,810,483
-416,029
-19% -$674K 0.37% 65
2024
Q3 		$4.43M Buy
2,226,512
+731,246
+49% +$1.75M 0.19% 72
2024
Q2 		$5.23M Sell
1,495,266
-1,280,938
-46% -$3.94M 0.14% 66
2024
Q1 		$7.69M Sell
2,776,204
-3,292,350
-54% -$8.28M 0.38% 40
2023
Q4 		$10.3M Sell
6,068,554
-81,288
-1% -$89.5K 0.63% 29
2023
Q3 		$6.33M Buy
6,149,842
+3,483,858
+131% +$4.96M 0.54% 51
2023
Q2 		$3.09M Buy
2,665,984
+576,692
+28% +$1.03M 0.18% 61
2023
Q1 		$3.15M Buy
2,089,292
+1,064,510
+104% +$2.67M 0.48% 55
2022
Q4 		$2.56M Buy
+1,024,782
New +$3.3M 0.46% 58
2020
Q2 		– Sell
-47,667
Closed -$560K – 80
2020
Q1 		$560K Buy
+47,667
New +$896K 0.26% 55
2019
Q3 		– Sell
-16,920
Closed -$315K – 57
2019
Q2 		$315K Sell
16,920
-22,416
-57% -$448K 0.15% 47
2019
Q1 		$961K Hold
39,336
– – 0.5% 33
2018
Q4 		$1.02M Buy
39,336
+8,577
+28% +$236K 0.7% 44
2018
Q3 		$974K Buy
+30,759
New +$1.15M 0.58% 39

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Clearline Capital's HRTX Position: Q2 2026 in Review

Clearline Capital reduced its Heron Therapeutics (HRTX) stake by 7% in Q2 2026, selling an estimated $683K and leaving 11,383,961 shares worth $4.86M. The position accounts for 0.29% of the portfolio, ranked #66.

Clearline Capital first reported a position in HRTX in Q3 2018 and has held it in 20 quarters since. The position peaked at $15.9M in Q4 2025. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Clearline Capital held 11,383,961 shares of Heron Therapeutics worth $4.86M as of Q2 2026.
  • Clearline Capital sold 851,278 Heron Therapeutics shares in Q2 2026, an estimated $683K.
  • Heron Therapeutics made up 0.29% of Clearline Capital's portfolio in Q2 2026, its #66 holding.
  • Clearline Capital first reported a position in Heron Therapeutics in Q3 2018 and has held it in 20 quarters since.
  • Clearline Capital's Heron Therapeutics position peaked at $15.9M in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Clearline Capital's 13F filing for Q2 2026, filed 14 Aug 2026.